Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of autologous adipose-derived expanded stem cells for extremely complex treatment-resistant perianal fistula
2010-024329-19Phase 2Active
- Sponsor
- FIBHULP
- Start
- Oct 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CX401 in anal fistula, sponsored by FIBHULP. Primary endpoints: Incidence of therapy-related adverse events and Safety process assessment. Started Oct 2011; status: active.
02
Drugs
CX401
03
Conditions
anal fistula
Beyond the preview
Go deeper on 2010-024329-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024329-19.